Daniel Teper
Founder & Chief Executive Officer NAYA Therapeutics
Wednesday 16th September 2026
Panel Discussion: Why 2026 Is the Year the Gap Between Clinical Ambition & Operational Capacity Must Begin to Close
9:15 am
- Panelists will examine the state of the radiopharmaceutical supply chain in 2026: where infrastructure investment is landing, where the workforce deficit is most acute, and how the shift in isotope preferences – from the established beta emitters toward alphas and emerging candidates – is creating new pressure across every manufacturing echelon
- Discussing the compounding risks that arise as programs progress into Phase II/III, where reliance on limited isotope supply, third-party manufacturing, logistics, and fragmented coordination from CDMO through to bedside must be managed in parallel to avoid disruption to clinical delivery
- Discuss what ‘commercial readiness’ actually means for radiopharmaceuticals and why the industry’s collective definition has to evolve beyond approval to include reliable, scalable, and distributed supply at the patient level
Thursday 17th September 2026
Chair’s Opening Remarks
8:55 am
